The Cautious Promise of GLP-1 Receptor Agonists

REFERENCES

1. 1.↵
   1. Wilding JPH,
   2. Batterham RL,
   3. Calanna S,
   4. et al.

   Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi: 10.1056/NEJMoa2032183

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Jastreboff AM,
   2. Aronne LJ,
   3. Ahmad NN,
   4. et al.

   Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi: 10.1056/NEJMoa2206038

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Harris E

   . Tirzepatide reduced disordered breathing in patients with sleep apnea. JAMA. 2024;332(6):447-448. doi: 10.1001/jama.2024.12873

   OpenUrlCrossRef
4. 4.↵
   1. Rubino D,
   2. Abrahamsson N,
   3. Davies M,
   4. et al.

   Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi: 10.1001/jama.2021.3224

   OpenUrlCrossRefPubMed